rgx-121

Generic: clemidsogene lanparvovec·Code: RGX-121

rgx-121: developed by 1 company · 2 FDA decisions. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
REGENXBIO Inc. (RGNX)Phase 3

FDA Decisions

CRL(RGNX)
FDA_MeetingFDA placed the Company's IND for the Phase I/II/III trial of RGX-121 for Mucopolysaccharidosis type II on clinical hold.(RGNX)

Frequently asked questions

Who is developing rgx-121?

rgx-121 is being developed by REGENXBIO Inc..

What is rgx-121's latest FDA decision?

The most recent tracked FDA decision for rgx-121 is CRL.

Get deeper analysis on rgx-121

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    rgx-121 — Drug Pipeline, Trials & FDA Status | BioSniper